Squarepoint’s Polaryx Therapeutics Inc PLYX Stock Holding History

Squarepoint’s Portfolio PLYX Stock Details PLYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,406	Closed	-$93.8K	–	5131
2026 Q1	$93.8K	Buy	+12,406	New	+$80.1K	﹤0.01%	4078

Other funds holding PLYX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return

Vanguard Global Advisers Malvern, Pennsylvania $215B AUM

Squarepoint's PLYX Position: Q2 2026 in Review

Squarepoint sold out of Polaryx Therapeutics Inc (PLYX) in Q2 2026, closing a stake of 12,406 shares — an estimated $93.8K sold.

Squarepoint first reported a position in PLYX in Q1 2026 and held it in 1 quarter. The position peaked at $93.8K in Q1 2026. 13 funds tracked by Wall St. Rank hold PLYX as of Q2 2026.

Squarepoint reported no remaining Polaryx Therapeutics Inc position as of Q2 2026 after selling out during the quarter.
Squarepoint sold 12,406 Polaryx Therapeutics Inc shares in Q2 2026, an estimated $93.8K.
Squarepoint first reported a position in Polaryx Therapeutics Inc in Q1 2026 and held it in 1 quarter.
Squarepoint's Polaryx Therapeutics Inc position peaked at $93.8K in Q1 2026.
13 funds tracked by Wall St. Rank held Polaryx Therapeutics Inc as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.